



Business Opportunities in Advanced Detection, Diagnosis and Minimally Invasive Interventions for Breast Cancer

12 November 2008

Merrimack Valley Venture Forum

Joseph Krieger

Chief Business Development Officer

978.604.2528

www.marvelmedtech.com





Big Problem: Disruptive Solution

- *NO CURE* for Breast Cancer

- Best Hope for Survival:
 - ❑ *Early Detection*
 - ❑ *Effective Intervention*





*MRI - Best technology available
for detecting breast cancer...*

Leverage MRI for breast cancer patients

AND

Transform MRI beyond diagnostics to
minimally invasive

Imaging Guided Intervention (IGI)

Imaging Guided Therapy (IGT)

Marvel Medtech's Advantage


- MR-Compatible Robotics
 - 'True 3D' IGI concept
- State-of-art MR Imaging (RF Coil)
- Advanced Visualization software 'engine'
 - Interactive (4D) control
 - First Mover



Growing Global Market

➤ Breast MR-IG Biopsy: **\$450MM in 2012**

□ **Solada-3D™**




➤ Breast Cancer Therapy: **\$8 Billion**


□ **Solada-R™ / Solada-4D™ / Solada-AT™**



Competitive Environment



“Go To Market” Strategy



Marvel Medtech's Team

- **Ray Harter: Founder, President**
 - Experienced Medtech Product Development, Commercial Operations

- **Cynthia Rose: Chief Financial Officer**
 - Entrepreneurial Medical Technology experience

- **Chris Barlow: Chief Technology Officer**
 - Proven leader – Advanced Medical Imaging Software Development

- **Joseph Krieger: Chief Business Development Officer**
 - Proven Clinical / Medical Technology / Software

Marvel Medtech's Team

➤ **Advisory Board**

- Lisa Arington – President, CEO, Shared Medical Services, Inc.
- Mark Gehring – CEO, Co-founder, Sharendipity
- Linda Leikness – COO, Deltanoid Pharmaceuticals, Inc.
- Gale Sisney, M.D. – Chief of Breast Imaging, UW Breast Center
- Larry Wells – President, CEO and Co-founder, NovaScan, LLC

➤ **Medical / Technical Board**

- Frederick Kelcz, Ph.D, M.D., Chief of Body MRI, UW Radiology
- Lenore Everson, M.D., Breast Radiology, U of MN Radiology
- Sean Fain, Ph.D., UW Medical Physics / Radiology
- Frank Fronczak, D. Eng., P.E., UW Biomedical Engineering
- Michael Zinn, Ph.D., UW Mechanical Engineering



Financing Summary

Solada-3D™ Product Development Plan

Phase 1
START-UP

Phase 2
DEVELOPMENT

Phase 3
LAUNCH

Phase 4
GROWTH

Commercial Hardware &
Software Development
Engineering

Complete Commercial
Product Development

Market Penetration

Product Safety Testing

Reg Compliance (510(k))

Develop & Deploy
SOLADA-R™

Start **SOLADA(3D)™**
Clinical Evaluation

Ramp-up Operations,
Marketing & Sales

SOLADA-4D™
SOLADA-AT™
Products



6-9 months

6-9 Months

Round 1

\$2,500,000

\$1,500,000





Financial Projections

Projected Income Statement (in \$ millions) for the year ending December 31

INCOME	2008	2009	2010	2011	2012
Sales Revenue	-	0.29	7.01	28.51	59.21
COGS	-	0.09	2.11	8.07	15.80
Net Revenue	-	0.20	4.90	20.44	43.41
EXPENSE					
G&A	0.20	0.46	1.19	1.92	2.42
R&D	0.40	2.17	3.12	3.89	5.95
S&M	0.05	0.33	1.36	3.49	4.46
Total Expense	0.65	2.97	5.67	9.30	12.83
EBITDA	(0.65)	(2.76)	(0.77)	11.13	30.58



Accomplishments & Milestones

Solada-3D™ Product Development Plan

Phase 1
START-UP

Third-Gen Prototype 90%
Ready for Clinical
Evaluation

GUI Software 'Engine'
@ 85% Functionality

Subcontract Partners
Engaged & 'Standing-By'

\$250,000

Phase 2
DEVELOPMENT

Phase 3
LAUNCH

Phase 4
GROWTH



Why Invest in Marvel Medtech?

- Big problem: Disruptive solution
- Strong, Deep Team
- 12 months to Solada-3DTM launch
- Strategic collaboration opportunities
- Strong IP moat
- Cash flow positive in year four
- 10x+ Acquisition Exit in 4-6 years



Ray Harter, President

Marvel Medtech, LLC

3591 Anderson Street, Suite 211A

Madison, WI 53704-2542

608.310.9560

608.310.9561 fax

ray@marvelmedtech.com

www.marvelmedtech.com

